BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 7708684)

  • 1. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Regenass U; Lydon NB
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2558-62. PubMed ID: 7708684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
    Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB
    Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.
    Andrejauskas-Buchdunger E; Regenass U
    Cancer Res; 1992 Oct; 52(19):5353-8. PubMed ID: 1394140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC; Keiser JA
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172).
    Ahn HY; Hadizadeh KR; Seul C; Yun YP; Vetter H; Sachinidis A
    Mol Biol Cell; 1999 Apr; 10(4):1093-104. PubMed ID: 10198059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ
    Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphorylation and PDGF-mediated cellular events by a quinoline derivative.
    Yagi M; Kato S; Kobayashi Y; Kubo K; Oyama S; Shimizu T; Nishitoba T; Isoe T; Nakamura K; Ohashi H; Kobayashi N; Iinuma N; Osawa T; Onose R; Osada H
    Exp Cell Res; 1997 Aug; 234(2):285-92. PubMed ID: 9260896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-derived growth factor stimulates sodium-dependent Pi transport in osteoblastic cells via phospholipase Cgamma and phosphatidylinositol 3' -kinase.
    Zhen X; Bonjour JP; Caverzasio J
    J Bone Miner Res; 1997 Jan; 12(1):36-44. PubMed ID: 9240723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
    Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
    Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
    Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
    Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
    Buchdunger E; Mett H; Trinks U; Regenass U; Müller M; Meyer T; Beilstein P; Wirz B; Schneider P; Traxler P
    Clin Cancer Res; 1995 Aug; 1(8):813-21. PubMed ID: 9816050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF.
    Loukinova E; Ranganathan S; Kuznetsov S; Gorlatova N; Migliorini MM; Loukinov D; Ulery PG; Mikhailenko I; Lawrence DA; Strickland DK
    J Biol Chem; 2002 May; 277(18):15499-506. PubMed ID: 11854294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
    J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway.
    Lassarre C; Ricort JM
    Endocrinology; 2003 Nov; 144(11):4811-9. PubMed ID: 12960057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BALB/c-3T3 fibroblasts resistant to growth inhibition by beta interferon exhibit aberrant platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor signal transduction.
    Mundschau LJ; Faller DV
    Mol Cell Biol; 1991 Jun; 11(6):3148-54. PubMed ID: 1645446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NIH 3T3 cells transfected with a yeast H(+)-ATPase have altered sensitivity to insulin, insulin growth factor-I, and platelet-derived growth factor-AA.
    Peterson EP; Martinez GM; Martinez-Zaguilan R; Perona R; Gillies RJ
    J Cell Physiol; 1994 Jun; 159(3):551-60. PubMed ID: 8188769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.